|From: UpAndAway (Rep: 27)||Date: 04/30/2019 09:17|
|Forum: Wall Street Pit - Msg #2784757 - List EDIT msgs ||Thread #674079013 (Rec: 0) |
|Allergan and Editas Medicine Announce Initial Data from Natural History Study to Evaluate Patients with Leber Congenital Amaurosis 10 (LCA10)|
AGN-151587 is set to be the first in vivo, or inside the body, CRISPR-based medicine administered to people anywhere in the world. In the planned Phase 1/2 clinical trial, Allergan and Editas Medicine intend to initiate patient screening mid-year and begin patient dosing in the second half of 2019, enrolling 10-20 patients in the U.S. and Europe.
Sent from my IPhone
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.